Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer

Hai, Luo; Shen, Kongchao; Li, Bo; Li, Ruiqi; Wang, Zeming; Xie, Zhixun

doi:10.3892/ol.2020.11633

Cited by 70 publications

(45 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous work showed that higher levels of CEA and CA19-9 were important biomarkers of CRC patients and predicted poor prognosis. 23 In the FCGBP -positive group, the levels of CEA (3.880 vs 77.049, p <0.001) and CA19-9 (8.610 vs 111.700, p <0.001) were lower than in the FCGBP -negative group. The number of positive nodes was similar between the two groups (3 vs 2, p =0.145).…”

Section: Resultsmentioning

confidence: 77%

IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients

Yuan¹,

Zhao

Hu³

et al. 2021

OTT

View full text Add to dashboard Cite

Background: The liver is the most frequent site for metastatic spread in colorectal cancer (CRC) patients, and these patients have much poorer prognosis than those without metastasis. Previous studies have shown that IgG Fc binding protein (FCGBP) plays important roles in tumorigenesis, progression, and prognosis, but its role in CRC metastasis remains unclear. Purpose: In this study, we are aimed to explore the significance of FCGBP in liver metastatic CRC (LMCRC) patients. Methods: We analyzed the expression of FCGBP RNA between CRC primary samples and liver metastatic samples in the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA). Next, we assessed the expression of FCGBP protein in 135 paired primary CRC (PC) samples and LMCRC samples. Finally, we explored the relationship between the expression features and clinicopathological characteristics. Results: The expression data of FCGBP were obtained from the GEO and TCGA databases. FCGBP RNA expression was evaluated between primary lesions (PC) and liver metastatic lesions (LM). FCGBP RNA was down-regulated in PC and LM, and especially lower in LM (p<0.001). Next, the expression of FCGBP protein was evaluated by an immunohistochemistry array in 135 paired primary tumor tissues and metastatic tissues. We found that FCGBP protein was down-regulated in primary lesions and metastatic lesions, especially in metastatic lesions. According to the immunohistochemistry score (SI), each cohort was divided into FCGBP-positive (SI=4-12) and FCGBP-negative (SI=0-3) groups. In both groups, the levels of CEA (PC group, 3.880 vs 77.049, p<0.001; LM group, 3.890 vs 14.239, p=0.008) and CA19-9 (PC group, 8.610 vs 111.700, p<0.001; LM group, 7.660 vs 19.380, p=0.037) were lower than those in the FCGBP-negative group. FCGBP positivity in the LM cohort was an independent risk factor in both overall survival (HR 1.573, 95% Cl [1.017-2.433], p=0.042) and disease-free survival (HR 1.869, 95% Cl [1.256-2.781], p=0.002). Conclusion: This study found a relationship between FCGBP expression and clinical information of LMCRC patients, and found that FCGBP expression decreased with disease development. The expression of FCGBP in liver metastasis is associated with both the overall and progressionfree survival. Our results show that FCGBP could be a promising prognostic factor for LMCRC.

show abstract

Section: Resultsmentioning

confidence: 77%

IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients

Yuan¹,

Zhao

Hu³

et al. 2021

OTT

View full text Add to dashboard Cite

show abstract

“…All the 22 patients conform to the surgical indications of taTME (for men, prostate hypertrophy, obesity, tumor diameter > 4 cm, mesenteric hypertrophy, lower anterior rectal wall tumor, pelvic stenosis, neoadjuvant radiotherapy caused by tissue plane unclear, and other "difficult pelvis" colorectal cancer patients) All patients diagnosed with rectal carcinoma via a pathological biopsy underwent comprehensive evaluations including routine physical examination, high‐definition chest‐abdomen computed tomography, pelvic magnetic resonance imaging (MRI), and the most overriding test—colonoscopy. Neuron‐specific enolase, carcinoembryonic antigen (CEA), cancer antigen (CA)19‐9, (CA)125, and (CA)242, used for the estimation of survival and prognosis, served as tumor biomarkers in the diagnosis of rectal cancer 11 . Correlation of preoperative, intraoperative, and postoperative information was analyzed, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…Neuron-specific enolase, carcinoembryonic antigen (CEA), cancer antigen (CA)19-9, (CA)125, and (CA)242, used for the estimation of survival and prognosis, served as tumor biomarkers in the diagnosis of rectal cancer. 11 Correlation of preoperative, intraoperative, and postoperative information was analyzed, respectively. (1) Patient demographics were evaluated (Table 1).…”

mentioning

confidence: 99%

Short‐term outcomes of medium‐low rectal cancer treated by taTME and experience of 22 cases

Shen

Wang

et al. 2021

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Background and Methods: Transanal total mesorectal excision (taTME) is a novel radical resection technique that may address the unsatisfactory functional and oncological outcomes of medium-low rectal cancers. Although its oncological safety remains unclear, taTME has demonstrable value in surgery, complications, and oncological outcomes. Here, we explore the short-term outcomes of rectal cancer after taTME and discuss the surgical experience. Twenty-two patients with medium-low rectal cancer who underwent taTME were retrospectively evaluated. Comprehensive demographic, oncological, and clinical data were analyzed and the perioperative state and postoperative follow-up were evaluated. Results: Over a median follow-up period of 24.4 (4-36) months, local recurrence occurred in one patient at 6 months postsurgery. Fecal incontinence was the most common postoperative complication, and 3-6 months of pelvic-floor-rehabilitation training greatly improved anal function Conclusions: taTME achieved satisfactory short-term outcomes in oncological complications and postoperative functions. Accurate intraoperative anatomical location, identification of the rectovesical fascia, and neuroprotection are critical. However, this procedure has a steep learning curve, and large samples and multicenter studies are required to substantiate its effectiveness. Discussion: We retrospectively analyzed the oncological and functional prognosis of 22 patients with colorectal cancer undergoing taTME surgery and preliminarily concluded taTME can be regarded as a safe and feasible treatment.

show abstract

“…Moreover, some biomarkers are utilized for predicting the prognosis of colon cancer patients. For instance, carbohydrate antigen 19-9 (CA19-9) has been identified as a predominant characteristic to diagnose colon cancer in clinical practice (14). CA19-9 is useful for the identification of outcomes of patients with stages I-III colorectal cancer 2 years after their operations (15).…”

Section: Introductionmentioning

confidence: 99%

A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

2021

View full text Add to dashboard Cite

Numerous colon cancer cases are resistant to chemotherapy based on oxaliplatin and suffer from relapse. A number of survival- and prognosis-related biomarkers have been identified based on database mining for patients who develop drug resistance, but the single individual gene biomarker cannot attain high specificity and sensitivity in prognosis prediction. This work was conducted aiming to establish a new gene signature using oxaliplatin resistance-related genes to predict the prognosis for colon cancer. To this end, we downloaded gene expression profile data of cell lines that are resistant and not resistant to oxaliplatin from the Gene Expression Omnibus (GEO) database. Altogether, 495 oxaliplatin resistance-related genes were searched by weighted gene co-expression network analysis (WGCNA) and differential expression analysis. As suggested by functional analysis, the above genes were mostly enriched into cell adhesion and immune processes. Besides, a signature was built based on four oxaliplatin resistance-related genes selected from the training set to predict the overall survival (OS) by stepwise regression and least absolute shrinkage and selection operator (LASSO) Cox analysis. Relative to the low risk score group, the high risk score group had dismal OS (P < 0.0001). Moreover, the area under the curve (AUC) value regarding the 5-year OS was 0.72, indicating that the risk score was accurate in the prediction of OS for colon cancer patients (AUC >0.7). Additionally, multivariate Cox regression suggested that the signature constructed based on four oxaliplatin resistance-related genes predicted the prognosis for colon cancer cases [hazard ratio (HR), 2.77; 95% CI, 2.03–3.78; P < 0.001]. Finally, external test sets were utilized to further validate the stability and accuracy of oxaliplatin resistance-related gene signature for prognosis of colon cancer patients. To sum up, this study establishes a signature based on four oxaliplatin resistance-related genes for predicting the survival of colon cancer patients, which sheds more light on the mechanisms of oxaliplatin resistance and helps identify colon cancer cases with a dismal prognostic outcome.

show abstract

Clinical significance and diagnostic value of serum NSE, CEA, CA19‑9, CA125 and CA242 levels in colorectal cancer

Cited by 70 publications

References 41 publications

IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients

IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients

Short‐term outcomes of medium‐low rectal cancer treated by taTME and experience of 22 cases

A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

Contact Info

Product

Resources

About